The estimated Net Worth of Kenneth W O'keefe is at least $90.1 Million dollars as of 11 August 2023. Mr. keefe owns over 1,241 units of Jazz Pharmaceuticals plc stock worth over $2,599,129 and over the last 17 years he sold JAZZ stock worth over $87,012,063. In addition, he makes $535,073 as Independent Director at Jazz Pharmaceuticals plc.
Kenneth has made over 19 trades of the Jazz Pharmaceuticals plc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 1,241 units of JAZZ stock worth $171,457 on 11 August 2023.
The largest trade he's ever made was selling 600,000 units of Jazz Pharmaceuticals plc stock on 9 March 2012 worth over $29,736,000. On average, Kenneth trades about 42,590 units every 114 days since 2007. As of 11 August 2023 he still owns at least 24,723 units of Jazz Pharmaceuticals plc stock.
You can see the complete history of Mr. keefe stock trades at the bottom of the page.
Kenneth W. O'Keefe serves as Independent Director of the Company. Mr. Kenneth W. O’Keefe has served as a member of our board of directors since the closing of the Azur Merger in January 2012 and was a director of Jazz Pharmaceuticals, Inc. from 2004 until the closing of the Azur Merger. Since January 2018, he has been Managing Director of Beecken Petty O’Keefe & Company, a private equity firm, which he co-founded. From November 2015 to January 2018, he was Chief Executive Officer, from January 2011 to November 2015, he was Managing Partner, and from 1997 to January 2011, he was Managing Director, of Beecken Petty O’Keefe & Company. He serves on the boards of several privately-held healthcare companies. He received a B.A. from Northwestern University and an M.B.A. from the University of Chicago.
As the Independent Director of Jazz Pharmaceuticals plc, the total compensation of Kenneth Keefe at Jazz Pharmaceuticals plc is $535,073. There are 18 executives at Jazz Pharmaceuticals plc getting paid more, with Bruce Cozadd having the highest compensation of $14,713,600.
Kenneth Keefe is 53, he's been the Independent Director of Jazz Pharmaceuticals plc since 2004. There are 17 older and 9 younger executives at Jazz Pharmaceuticals plc. The oldest executive at Jazz Pharmaceuticals plc is Catherine Sohn, 67, who is the Independent Director.
Kenneth's mailing address filed with the SEC is 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4, L2, .
Over the last 17 years, insiders at Jazz Pharmaceuticals plc have traded over $1,513,676,247 worth of Jazz Pharmaceuticals plc stock and bought 1,319,315 units worth $25,188,964 . The most active insiders traders include Michael W Michelson, Patrick G Enright und Jp Iii Llckkr Partners Iii,.... On average, Jazz Pharmaceuticals plc executives and independent directors trade stock every 11 days with the average trade being worth of $5,162,934. The most recent stock trade was executed by Mary Elizabeth Henderson on 6 September 2024, trading 1,410 units of JAZZ stock currently worth $152,703.
jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni
Jazz Pharmaceuticals plc executives and other stock owners filed with the SEC include: